Results 141 to 150 of about 86,295 (314)

Distinct Immunomodulatory Strategies Guide Mesenchymal Stromal/Stem Cell‐Mediated Bone Regeneration

open access: yesAdvanced Science, EarlyView.
Bone regeneration by mesenchymal stem cells is strongly influenced by immune signals. This study shows that priming stem cells with regulatory immune cells or an inflammation‐resolving lipid molecule enhances bone formation through distinct immune pathways.
Salwa Suliman   +5 more
wiley   +1 more source

Rhomboid blepharoplasty and cryotherapy for the treatment of a squamous cell carcinoma on the lower eyelid in a horse [PDF]

open access: yes, 2018
Beard   +36 more
core   +2 more sources

Engineered Bacteria Factory Integrating Drug Delivery and Antibody Manufacture for Activating the STING Signal Pathway Mediated Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
To address the limitations of protein‐based ICIs in applications, this study constructed an engineered bacterium, HRB, capable of expressing aCD47 in hypoxic TME. Through the Schiff base reaction, responsive liposomes (LC) loaded with the STING agonist cGAMP were connected to the surface of bacteria to form HRB@LC.
Peng‐Shuo Dong   +9 more
wiley   +1 more source

Delivery of Pleckstrin‐Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis

open access: yesAdvanced Science, EarlyView.
Current therapies curb tumor growth but not metastasis. Obscurin, a giant metastasis suppressor lost in breast cancer, restrains PI3K/Akt signaling but is impractical to restore. We deploy a mini‐obscurin, comprising the obscurin‐PH‐domain, which sequesters PI3K‐p85, potently suppressing invasion and metastasis.
Matthew Eason   +12 more
wiley   +1 more source

Context‐Dependent Role of GDF15: GDF15+ Tumor‐Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis

open access: yesAdvanced Science, EarlyView.
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou   +9 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

open access: yesAdvanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey   +6 more
wiley   +1 more source

Major vessel excision in retroperitoneal lymph node dissection.

open access: yesCanadian journal of surgery. Journal canadien de chirurgie, 1993
Retroperitoneal malignant tumours, both primary and metastatic, may involve surrounding structures such as the aorta and vena cava, making complete tumour excision difficult. En bloc resection of major blood vessels should be considered in such cases. The authors describe three patients who underwent excision of major blood vessels with retroperitoneal
C G, Krahn   +3 more
openaire   +1 more source

Humanized and Charge‐Optimized CSPG4‐Specific CAR‐T Cells show Enhanced Efficacy against Head and Neck Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
CSPG4 is identified as a high‐value, stemness‐associated target in HPV‐negative HNSCC. By implementing rational biophysical engineering, a humanized and charge‐optimized CAR is developed to overcome tonic signaling‐induced exhaustion. This strategy induces a profound transcriptomic shift toward a rejuvenated, stem‐like memory state, significantly ...
Xiang Xu   +13 more
wiley   +1 more source

Bilateral medial iliac lymph node excision by a ventral laparoscopic approach: technique description. [PDF]

open access: yesJ Vet Med Sci, 2017
Lim H   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy